I'm just home from a day at City of Hope, I've heard the reverse split was rejected and the company plans another vote, but I've seen no release from them, or anything they're doing to buoy the stock.
I believe the only way investors should consider a R/S is if it's no more than 1 for 3 bringing our O/S down to roughly 60 million shares. That's a number that still gives them tremendous room for growth, and if they'd achieve some of their goals should bring a share price that at least approaches $1, if it doesn't exceed it.
Of course if they say, and do nothing, the price stays roughly where it is now. If you're still an investor here you should believe we'll be getting patent approvals and we'll be seeing efficacy demonstrated in trials by late this year. If that in fact is the case, by late this year the stock price should be dramatically higher, with, or without an R/S. While I'd prefer no R/S at all, a small one which could aid us to achieve Nasdaq requirements in 2020 to 2022 would be reasonable. One which instantaneously gave us a share price in excess of $4 would not, as Nasdaq rules require far more than just a $4 share price, and that requires building a business, not simply achieving a share price. I frankly don't believe that we can meet Nasdaq requirements without having product sales, unless we do so by achieving a partnership where earnings from achieving milestones are possible before product sales are initiated.
I believe the key to the company's growth should come with communicating with investors. Discuss the patents, upcoming trials, and make the information publicly available by putting information in the clinical trials database. Trials do not need to be done in the U.S. to be included in the database, but if the information is there, and if it's updated as things change, no one would need to questions whether it's being done with diseased, or healthy patients, they wouldn't need to question when it's scheduled to begin, or end, or how the trial is to be done, or where it's to be done, all the information would be there. Certainly things can change, and the company is free to update the information, but knowledgeable investors will value the information, and you'll see it in the stock price. Likewise, if they'd speak to investors and Analysts when they release the quarterly it should create value, provided they're not evasive in answering questions.
Gary
I believe the only way investors should consider a R/S is if it's no more than 1 for 3 bringing our O/S down to roughly 60 million shares. That's a number that still gives them tremendous room for growth, and if they'd achieve some of their goals should bring a share price that at least approaches $1, if it doesn't exceed it.
Of course if they say, and do nothing, the price stays roughly where it is now. If you're still an investor here you should believe we'll be getting patent approvals and we'll be seeing efficacy demonstrated in trials by late this year. If that in fact is the case, by late this year the stock price should be dramatically higher, with, or without an R/S. While I'd prefer no R/S at all, a small one which could aid us to achieve Nasdaq requirements in 2020 to 2022 would be reasonable. One which instantaneously gave us a share price in excess of $4 would not, as Nasdaq rules require far more than just a $4 share price, and that requires building a business, not simply achieving a share price. I frankly don't believe that we can meet Nasdaq requirements without having product sales, unless we do so by achieving a partnership where earnings from achieving milestones are possible before product sales are initiated.
I believe the key to the company's growth should come with communicating with investors. Discuss the patents, upcoming trials, and make the information publicly available by putting information in the clinical trials database. Trials do not need to be done in the U.S. to be included in the database, but if the information is there, and if it's updated as things change, no one would need to questions whether it's being done with diseased, or healthy patients, they wouldn't need to question when it's scheduled to begin, or end, or how the trial is to be done, or where it's to be done, all the information would be there. Certainly things can change, and the company is free to update the information, but knowledgeable investors will value the information, and you'll see it in the stock price. Likewise, if they'd speak to investors and Analysts when they release the quarterly it should create value, provided they're not evasive in answering questions.
Gary
2
